Network Pharmacology Analysis of Orally Bioavailable SARS-CoV-2 Protease Inhibitor Shows Synergistic Targets to Improve Clinical Efficacy
Arun HS Kumar1★★ Corresponding author
- 1School of Veterinary Medicine, Univer- sity College Dublin, Belfield, Dublin, IRELAND.
CORRESPONDENCE
Arun HS Kumar
School of Veterinary Medicine, Univer- sity College Dublin, Belfield, Dublin, IRELAND.
Received: 14-04-2021; Revised: 30-04-2021; Accepted: 02-05-2021.
Volume 7, Issue 2 · pp. 21–24 · PUBLISHED · DOI: 10.5530/bems.7.2.8
ABSTRACT
Introduction: Orally bioavailable SARS-CoV-2 antiviral drugs will significantly improve the clinical management of the disease. PF07321332 (PF32) one such orally bioavailable SARS- CoV-2 protease inhibitor which can be helpful to prevent viral replication in the host. Materials and Methods: Hence this study evaluated the network pharmacology of PF32 using established methods to predict its potential safety and efficacy. Results:PF32 was selective against SARS-CoV-2 proteases without any affinity against SARS-CoV-2 RNA polymerase or its spike protein. While PF32 showed pharmacologically relevant affinity against several targets in human tissues. The target profiling of PF32 indicated a fourfold selectivity towards several proteases in human tissues with an affinity (IC50) ranging from 26 to 41 nM. Conclusion: The predicted inhibitory effects of PF32 against both host and viral proteases may have synergistic effects for superior clinical efficacy.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Kumar, A. H. (). Network Pharmacology Analysis of Orally Bioavailable SARS-CoV-2 Protease Inhibitor Shows Synergistic Targets to Improve Clinical Efficacy. Biology, Engineering, Medicine and Science Reports, 7(2), 21–24. https://doi.org/10.5530/bems.7.2.8